Cargando…
Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level
PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449641/ https://www.ncbi.nlm.nih.gov/pubmed/34548782 http://dx.doi.org/10.2147/DDDT.S327506 |
_version_ | 1784569457580965888 |
---|---|
author | Huang, Shanqing Li, Lu Wang, Zhanzhang Xiao, Tao Li, Xiaolin Liu, Shujing Zhang, Ming Lu, Haoyang Wen, Yuguan Shang, Dewei |
author_facet | Huang, Shanqing Li, Lu Wang, Zhanzhang Xiao, Tao Li, Xiaolin Liu, Shujing Zhang, Ming Lu, Haoyang Wen, Yuguan Shang, Dewei |
author_sort | Huang, Shanqing |
collection | PubMed |
description | PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring (TDM) data to guide individualized therapy. PATIENTS AND METHODS: Plasma concentration data (330 measurements from 121 patients) were analyzed using a nonlinear mixed-effects modeling (NONMEM) approach with first-order conditional estimation with interaction (FOCE I). The concentrations of amisulpride were detected by HPLC-MS/MS. Age, weight, sex, combination medication history and renal function status were evaluated as main covariates. The model was internally validated using goodness-of-fit, bootstrap and normalized prediction distribution error (NPDE). Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model. RESULTS: A one-compartment model with first-order absorption and elimination was found to adequately characterize amisulpride concentration in Chinese patients with schizophrenia. The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively. Age significantly affected the clearance of amisulpride and the final model was as follows: CL/F=1.04×(AGE/32)(−0.624) (L/h). To avoid exceeding the laboratory alert level (640 ng/mL), the model-based simulation results showed that the recommended dose of amisulpride was no more than 600 mg/d for patients aged 60 years, 800 mg/d for those aged 40 years and 1200 mg/d for those aged 20 years, respectively. CONCLUSION: Dosage optimization of amisulpride can be carried out according to age to reduce the risk of adverse reactions. The model can be used as a suitable tool for designing individualized therapy for Chinese patients with schizophrenia. |
format | Online Article Text |
id | pubmed-8449641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84496412021-09-20 Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level Huang, Shanqing Li, Lu Wang, Zhanzhang Xiao, Tao Li, Xiaolin Liu, Shujing Zhang, Ming Lu, Haoyang Wen, Yuguan Shang, Dewei Drug Des Devel Ther Original Research PURPOSE: To explain the high inter-individual variability (IIV) and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride, a population pharmacokinetic (PPK) model in Chinese patients with schizophrenia was built based on therapeutic drug monitoring (TDM) data to guide individualized therapy. PATIENTS AND METHODS: Plasma concentration data (330 measurements from 121 patients) were analyzed using a nonlinear mixed-effects modeling (NONMEM) approach with first-order conditional estimation with interaction (FOCE I). The concentrations of amisulpride were detected by HPLC-MS/MS. Age, weight, sex, combination medication history and renal function status were evaluated as main covariates. The model was internally validated using goodness-of-fit, bootstrap and normalized prediction distribution error (NPDE). Recommended dosage regimens for patients with key covariates were estimated on the basis of Monte Carlo simulations and the established model. RESULTS: A one-compartment model with first-order absorption and elimination was found to adequately characterize amisulpride concentration in Chinese patients with schizophrenia. The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively. Age significantly affected the clearance of amisulpride and the final model was as follows: CL/F=1.04×(AGE/32)(−0.624) (L/h). To avoid exceeding the laboratory alert level (640 ng/mL), the model-based simulation results showed that the recommended dose of amisulpride was no more than 600 mg/d for patients aged 60 years, 800 mg/d for those aged 40 years and 1200 mg/d for those aged 20 years, respectively. CONCLUSION: Dosage optimization of amisulpride can be carried out according to age to reduce the risk of adverse reactions. The model can be used as a suitable tool for designing individualized therapy for Chinese patients with schizophrenia. Dove 2021-09-14 /pmc/articles/PMC8449641/ /pubmed/34548782 http://dx.doi.org/10.2147/DDDT.S327506 Text en © 2021 Huang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Huang, Shanqing Li, Lu Wang, Zhanzhang Xiao, Tao Li, Xiaolin Liu, Shujing Zhang, Ming Lu, Haoyang Wen, Yuguan Shang, Dewei Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title_full | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title_fullStr | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title_full_unstemmed | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title_short | Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level |
title_sort | modeling and simulation for individualized therapy of amisulpride in chinese patients with schizophrenia: focus on interindividual variability, therapeutic reference range and the laboratory alert level |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449641/ https://www.ncbi.nlm.nih.gov/pubmed/34548782 http://dx.doi.org/10.2147/DDDT.S327506 |
work_keys_str_mv | AT huangshanqing modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT lilu modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT wangzhanzhang modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT xiaotao modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT lixiaolin modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT liushujing modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT zhangming modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT luhaoyang modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT wenyuguan modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel AT shangdewei modelingandsimulationforindividualizedtherapyofamisulprideinchinesepatientswithschizophreniafocusoninterindividualvariabilitytherapeuticreferencerangeandthelaboratoryalertlevel |